Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression - Yahoo Finance

Submitted by Anonymous (not verified) on Tue, 10/15/2019 - 12:00

Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression  Yahoo Finance